Humira

Humira is a prescription biologic medication whose active ingredient is adalimumab, supplied as a solution for subcutaneous injection. It belongs to the tumor necrosis factor (TNF) inhibitor class and is marketed in the European Union. As a biologic disease‑modifying antirheumatic drug (bDMARD), Humira is used to target inflammatory processes in several autoimmune conditions. It is prescribed for adults and children when other therapies have not provided adequate control.

Humira (adalimumab) is indicated for several chronic inflammatory and autoimmune disorders where modulation of tumor necrosis factor‑α is required.

- Rheumatoid arthritis – to reduce signs and symptoms and to inhibit structural joint damage. - Psoriatic arthritis – to improve joint inflammation and skin lesions. - Ankylosing spondylitis – to alleviate spinal pain and stiffness. - Crohn’s disease – to induce and maintain clinical remission. - Ulcerative colitis – to achieve remission and mucosal healing. - Plaque psoriasis – to clear skin plaques and reduce scaling.

Adalimumab may cause a range of adverse reactions, from mild to severe, that are reported in clinical use.

Common: - Injection‑site pain, redness, or swelling. - Upper respiratory tract infections such as sinusitis or nasopharyngitis. - Headache. - Mild rash or pruritus. - Nausea or abdominal discomfort. - Fatigue.

Serious: - Serious infections, including tuberculosis and opportunistic pathogens. - Reactivation of hepatitis B virus. - New or worsening heart failure. - Demyelinating disorders such as multiple sclerosis‑like events. - Lupus‑like syndrome with joint pain and serology changes. - Certain malignancies, notably lymphoma and skin cancers.

Before initiating therapy with Humira, several safety considerations should be evaluated to minimize risk.

- Screen for latent tuberculosis and treat before starting therapy. - Assess for active infections; postpone treatment if infection is present. - Evaluate history of chronic or recurrent infections, including hepatitis B or C. - Review cardiac status, especially in patients with moderate to severe heart failure. - Consider potential for demyelinating disease or multiple sclerosis. - Discuss pregnancy, lactation, and contraception plans, as safety data are limited. - Monitor for signs of malignancy during long‑term use.

Adalimumab can interact with other medicines, affecting efficacy or safety.

Avoid: - Live vaccines (e.g., measles, varicella) due to risk of infection. - Concomitant use with other biologic immunosuppressants (e.g., abatacept, rituximab) unless specifically indicated.

Use with caution: - Systemic corticosteroids, which may increase infection risk. - Immunosuppressive agents such as azathioprine or methotrexate. - Antiviral therapy for hepatitis B, requiring close monitoring. - Cyclosporine or other calcineurin inhibitors. - Anticoagulants, as injection site bleeding may be enhanced.